Business Wire

BASIS-TECHNOLOGIES

Share
Basis Technologies announces Consolidator: a new automation tool to support digital transformation and business innovation

Basis Technologies today announces the introduction of Consolidator, a new addition to its extensive range of automation tools. Consolidator performs the technical analysis and merge of SAP ECC systems, including those running on HANA, with minimal user intervention. Automation reduces the risk and cost of the overall process, allowing more businesses to realize the benefits of SAP system consolidation.

A time of change

Sixty-four percent of IT and marketing executives recently surveyed by Gartner said that they expect to transform into a digital business by the end of 20171 .

In such a dynamic, disruptive environment, business initiatives like digital transformation are becoming commonplace. A shift to cloud-based Enterprise Resource Planning (ERP) solutions, including S/4HANA from SAP, is also underway, and M&A activity continues to gather pace. Meanwhile, potentially huge opportunities lurk inside inefficient SAP system landscapes built up over decades of acquisitions and reorganizations.

All of these factors are combining to generate an ever-increasing level of demand for SAP system consolidation projects.

A new way to unlock value

To date, a limited number of tools have been available to support system consolidation. This has resulted in processes which feature an unavoidably high level of manual effort, with the corresponding business risk that such methods naturally bring.

Consolidator offers the chance to automate a critical - and labor-intensive - portion of the consolidation process: the technical merge. Risk and necessary resource inputs are dramatically reduced, enabling businesses to unlock value, focus on innovation, reduce cost of ownership and prepare for a new generation of enterprise solutions.

"Businesses should give more thought to optimization of the SAP systems that enable great customer experiences. Too much cash is being wasted on simply maintaining existing processes and stabilizing legacy infrastructure." said Martin Metcalf, Chief Executive Officer of Basis Technologies. "There is just not enough focus placed on unlocking the latent value within these assets through the use of automation technologies such as Consolidator"

To learn more about Consolidator, visit www.basistechnologies.com/consolidator

About Basis Technologies

Basis Technologies have delivered innovative software solutions for SAP for almost 20 years. We focus on automation tools that enable continuous delivery, helping our customers to keep pace with theirs. Our products support the adoption of methodologies such as Agile and DevOps in an SAP environment, and our client list includes a selection of major multinational companies such as BP, Unilever and Ralph Lauren.

To find out more, visit www.basistechnologies.com .

####

1. Navigate Your Way to Digital Business Transformation With These Resources, Don Scheibenreif, VP Distinguished Analyst, Gartner (August 2015)

2. Consolidator does not support the analysis or merge of transactional or master data. Other tools may be required.

Contact:

Basis Technologies
Peter Yabsley
Head of Product Marketing
+44 7867 335 310
peter.yabsley@basistechnologies.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye